Akebia announces ‘multiple positive business updates’

Akebia (AKBA) Therapeutics announced multiple positive business updates. As of January, Vafseo tablets are available in the U.S. for adult patients with anemia due to chronic kidney disease on dialysis for at least three months, and shipment of product to dialysis centers has commenced. In addition, Akebia recently signed a Vafseo commercial supply agreement with a leading dialysis organization. Akebia now has contracts in place with dialysis organizations caring for nearly 100% of dialysis patients in the U.S. As previously announced, Vafseo qualifies for the Transitional Drug Add-On Payment Adjustment reimbursement as directed by the Centers for Medicare & Medicaid Services, and CMS has published billing guidance and reimbursement rates.